China Health Group Ltd. announced its consolidated financial results for the fiscal year ending March 31, 2025. The company reported a revenue of HK$38.943 million, a decrease from HK$59.930 million in the previous year. The cost of sales also dropped to HK$29.708 million from HK$46.292 million, resulting in a gross profit of HK$9.235 million compared to HK$13.638 million last year. Other income for the year was HK$16.689 million, down from HK$39.085 million, while the net other loss improved to HK$6.575 million from HK$24.689 million in 2024. The company recorded a net impairment loss of financial assets of HK$17.642 million, slightly better than the HK$18.435 million reported the previous year. Selling and distribution expenses fell significantly to HK$6.138 million from HK$17.768 million. However, administrative expenses increased sharply to HK$62.695 million from HK$33.798 million. The operating loss widened to HK$67.126 million from HK$41.967 million in 2024. The segment results showed a decline in various business areas. Revenue from distribution and service in medical equipment and consumables was HK$27.216 million, down from HK$45.334 million. Income from hospital operation and management services decreased to HK$11.232 million from HK$14.081 million. No specific guidance or outlook for the coming year was provided in the report.